
Triumphant in trade talks, Trump and his tariffs still face a challenge in federal court
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
Now it goes on to Round Two.
Advertisement
On Thursday, the 11 judges on the U.S. Court of Appeals for the Federal Circuit in Washington, which typically specializes in patent law, are scheduled to hear oral arguments from the Trump administration and from the states and businesses that want his sweeping import taxes struck down.
That court earlier allowed the federal government to continue collecting Trump's tariffs as the case works its way through the judicial system.
The issues are so weighty — involving the president's power to bypass Congress and impose taxes with huge economic consequences in the United States and abroad — that the case is widely expected to reach the U.S. Supreme Court, regardless of what the appeals court decides.
Advertisement
Trump is an unabashed fan of tariffs. He sees the import taxes as an all-purpose economic tool that can bring manufacturing back to the United States, protect American industries, raise revenue to pay for the massive tax cuts in his 'One Big Beautiful Bill,'' pressure countries into bending to his will, even end wars.
The U.S. Constitution gives the power to impose taxes — including tariffs — to Congress. But lawmakers have gradually relinquished power over trade policy to the White House. And Trump has made the most of the power vacuum, raising the average U.S. tariff to more than 18%, highest since 1934, according to the Budget Lab at Yale University.
At issue in the pending court case is Trump's use of the 1977 International Emergency Economic Powers Act (IEEPA) to impose sweeping tariffs without seeking congressional approval or conducting investigations first. Instead, he asserted the authority to declare a national emergency that justified his import taxes.
In February, he cited the illegal flow of drugs and immigrants across the U.S. border to slap tariffs on Canada, China and Mexico. Then on April 2 — 'Liberation Day,'' Trump called it — he invoked IEEPA to announce 'reciprocal'' tariffs of up to 50% on countries with which the United States ran trade deficits and a 10% 'baseline'' tariff on almost everybody else. The emergency he cited was America's long-running trade deficit.
Trump later suspended the reciprocal tariffs, but they remain a threat: They could be imposed again Friday on countries that do not pre-empt them by reaching trade agreements with the United States or that receive letters from Trump setting their tariff rates himself.
Advertisement
The plaintiffs argue that the emergency power laws does not authorize the use of tariffs. They also note that the trade deficit hardly meets the definition of an 'unusual and extraordinary'' threat that would justify declaring an emergency under the law. The United States, after all, has run trade deficits — in which it buys more from foreign countries than it sells them — for 49 straight years and in good times and bad.
The Trump administration argues that courts approved President Richard Nixon's emergency use of tariffs in a 1971 economic crisis. The Nixon administration successfully cited its authority under the 1917 Trading With Enemy Act, which preceded and supplied some of the legal language used in IEEPA.
In May, the trade court rejected the argument, ruling that Trump's Liberation Day tariffs 'exceed any authority granted to the President'' under the emergency powers law.
'The president doesn't get to use open-ended grants of authority to do what he wants,'' said Reilly Stephens, senior counsel at the Liberty Justice Center, a libertarian legal group that is representing businesses suing the Trump administration over the tariffs.
In the case of the drug trafficking and immigration tariffs on Canada, China and Mexico, the trade court ruled that the levies did not meet IEEPA's requirement that they 'deal with'' the problem they were supposed to address.
The court challenge does not cover other Trump tariffs, including levies on foreign steel, aluminum and autos that the president imposed after Commerce Department investigations concluded that those imports were threats to U.S. national security.
Nor does it include tariffs that Trump imposed on China in his first term — and President Joe Biden kept — after a government investigation concluded that the Chinese used unfair practices to give their own technology firms an edge over rivals from the United States and other Western countries.
Advertisement
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Susquehanna Lowers Wolfspeed (WOLF) PT to $1.50 Amid Q2 Semiconductor Preview
Wolfspeed Inc. (NYSE:WOLF) is one of the tech stocks to buy according to analysts. On July 22, Susquehanna lowered the price target for Wolfspeed from $3 to $1.50, while maintaining a Neutral rating on the shares. The adjustment came as part of the firm's Q2 preview for the semiconductor group, with the firm expecting in-line to modest upside reports for the current quarter, driven by tariff-related demand pull-ins and sustained AI strength. However, Susquehanna's analysts did note increased uncertainty for the latter half of 2025 within the broader semiconductor market. In FQ3 2025, Wolfspeed showed a sequential revenue growth of 50% at its Mohawk Valley facility, which contributed $78 million in revenue. The company has also established a fully automated 200-millimeter manufacturing footprint for silicon carbide solutions and received ~$192 million in cash tax refunds from the Section 48D advanced manufacturing tax credit, which boosted liquidity. Close-up of Silicon Die are being Extracted from Semiconductor Wafer and Attached to Substrate by Pick and Place Machine. Computer Chip Manufacturing at Fab. Semiconductor Packaging Process. Additionally, Wolfspeed is actively engaging with customers for sampling 200-millimeter materials and pursuing new contracts for 200-millimeter wafer supply. But at the same time, the company is undergoing a restructuring, which includes a 30% reduction in its senior leadership team and projected restructuring charges of $400 million to $450 million for FY2025. Free cash flow during the quarter was also negative, at $168 million. Wolfspeed Inc. (NYSE:WOLF) is a semiconductor company that focuses on silicon carbide and gallium nitride/GaN technologies in Europe, Hong Kong, China, the rest of Asia-Pacific, the US, and internationally. While we acknowledge the potential of WOLF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16 minutes ago
- Yahoo
MultiSensor AI Holdings Upgrades Asset Health Platform with MSAI Connect 2.0, Adds Enhanced AI, Seamless EAM Integration
MultiSensor AI Holdings Inc. (NASDAQ:MSAI) is one of the tech stocks to buy according to analysts. On July 9, MultiSensor AI Holdings unveiled MSAI Connect 2.0. This upgrade to their asset health monitoring platform further reduces unplanned downtime, streamlines operations, and provides users with more actionable insights. MSAI Connect 2.0 introduces several key enhancements. Its AI functionality is supported by camera disturbance detection, which alerts operators to unintended sensor movements that might affect critical asset monitoring. Additionally, improved person and motion detection logic has been incorporated to reduce false-positive alerts. Photo by Vishnu Mohanan on Unsplash The platform integrates seamlessly with customers' existing Enterprise Asset Management/EAM systems. This creates a link between identifying issues and initiating corrective actions. MultiSensor AI Holdings Inc. (NASDAQ:MSAI) builds and deploys intelligent multi-sensing platforms with edge and cloud software solutions that use AI in the US and internationally. While we acknowledge the potential of MSAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
26 minutes ago
- Yahoo
Citi Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data